Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
AssigneeRhone-Poulenc Rorer Pharmaceuticals Inc.
InventorsAlfred P. Spada, Paul E. Persons, Alexander Levitzki, Chaim Gilon
Life of this patent
Estimating the term…
Abstract
Methods of inhibiting cell proliferation in a patient suffering from such disorder comprising the use of a styryl-substituted heteroaryl compound wherein the heteroaryl group is a monocyclic ring with 1 or 2 heteroatoms, or a bicyclic ring with 1 to about 4 heteroatoms, said compound optionally substituted or polysubstituted, with the proviso that when said ring is polysubstituted, the substituents do not have a common point of attachment to said ring, and those compounds wherein no substituent on the heteroaryl group is a carboxy group or an ester group, and pharmaceutical compositions comprising such compounds.
Claims12
A compound of the following formula ##STR8## wherein:
- R.sub.1 is --CN;
- R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each independently lower alkyl, --H, lower alkoxy or --OH, with the provisos that at least two of R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are not --H and that R.sub.4, R.sub.5 or R.sub.6 is not lower alkoxy when R.sub.7 or R.sub.8 is lower alkoxy;
- and
- R.sub.4 and R.sub.6 are also each independently halo.
Dependencies are inferred from the claim text.